IL33 and neoplasm: Similarly, in the CT26 adenocarcinoma mouse model, administration of recombinant IL-33 (rIL-33) enhanced, while inhibition of IL-33 diminished, the expansion of ST2+ Treg cells in tumor tissue and spleen, resulting in tumor growth [118].